At Federal Circuit Hearing, Plaintiffs in Myriad Case Fight to Keep Gene Patentability Issue on the Table | GenomeWeb

Originally published July 20.

WASHINGTON — Plaintiffs challenging Myriad's patents on isolated BRCA1 and BRCA2 gene sequences argued before the Court of Appeals for the Federal Circuit today that the firm's composition-of-matter claims related to its BRACAnalysis test are so broad — covering large stretches of gene sequences and "every conceivable form of DNA" — that, if upheld, would stop others from inventing new diagnostics and treatments based on that basic genetic knowledge.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.